• 1
    Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;3:191193.
  • 2
    Bousquet J, Demoly P. Specific immunotherapy – an optimistic future. Allergy 2006;61:11551158.
  • 3
    Valovirta E, Jacobsen L, Ljorring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006;61:11771183.
  • 4
    Durham SR, Sun Ying, Varney VA, Jacobson MA, Sudderick RM, Mackay IS et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996;97:13561365.
  • 5
    Wilson DR, Nouri-ARIA KT, Walker SM, Pajno GB, O’Brien F, Jacobson MR et al. Grass Pollen Immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. J Allergy Clin Immunol 2001;107:971976.
  • 6
    Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:12051214.
  • 7
    Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003;111:12551261.
  • 8
    Savolainen J, Laaksonen K, Rantio-Lehtimäki A, Terho EO. Increased expression of allergen induced in vitro IL-10 and IL-18 mRNA in PBMC of allergic rhinitis patients after specific immunotherapy. Clin Exp Allergy 2004; 34:413419.
  • 9
    Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006;61:11841190.
  • 10
    Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995;6552:8891.
  • 11
    Hofstra CL, Van Ark I, Hofman G, Kool M, Nijkamp FR, Van Oosterhout AJM. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsives, eosinophilia, and serum IgE levels. J Immunol 1998;161:50545060.
  • 12
    Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S et al. IL-18 although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 1999;96: 1396213966.
  • 13
    Aversa G, Carballido J, Punnonen J, Chang C-CJ, Hauser T, Cocks BG et al. SLAM and its role in T cell activation and Th cell responses. Immunol Cell Biol 1997;75:202205.
  • 14
    Cocks BG, Chang C-CJ, Carballido JM, Yssel H, De Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995;376:260263.
  • 15
    Hämäläinen H, Meissner S, Lahesmaa R. Signaling lymphocytic activation molecule (SLAM) is differentially expressed in human Th1 and Th2 cells. J Immunol Methods 2000;42:919.
  • 16
    Laaksonen K, Junikka M, Lahesmaa R, Terho EO, Savolainen J. In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy. J Allergy Clin Immunol 2003;112:11711177.
  • 17
    Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587596.
  • 18
    Zhang DH, Cohn L, Ray P, Bottomly K, Ray A. Transcription factor GATA-3 is differentially expressed in murine Th1 and Th2 cells and controls Th2-specific expression of the interleukin-5gene. J Biol Chem 1997;272:2159721603.
  • 19
    Ylikoski E, Lund R, Kyläniemi M, Filen S, Kilpeläinen M, Savolainen J et al. IL-12 up-regulates T-bet independently of IFN-gamma in human CD4+ T cells. Eur J Immunol 2005;35:32973306.
  • 20
    Higashi N, Gesser B, Kawana S, Thestrup-Pedersen K. Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis. J Allergy Clin Immunol 2001;108:607614.
  • 21
    Ho L-P, Davis M, Denison A, Wood FT, Greening AP. Reduced interleukin-18 levels in Bal specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects. Chest 2002;121:14211426.
  • 22
    El-Mezzein RE, Matsumoto T, Nomiyama H, Miike T. Increased secretion of IL-18 in vitro by peripheral blood mononuclear cells of patients with bronchial asthma and atopic dermatitis. Clin Exp Immunol 2001;126:193198.
  • 23
    Verhaeghe B, Gevaert P, Holtappels G, Lukat KF, Lange B, Van Cauwenberge P et al. Up-regulation of IL-18 in allergic rhinitis. Allergy 2002;57:825830.
  • 24
    Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol 1997;99:254260.
  • 25
    Varney VA, Hamid QA, Gaga M, Ying S, Jacobson M, Frew AJ et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993;92:644651.
  • 26
    Dehlink E, Eiwegger T, Gerstmayr M, Kampl E, Bohle B, Chen KW et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006;36:3239.
  • 27
    Ferrante P, Fusi ML, Sarasella M, Caputo D, Biasin M, Trabattoni D et al. Cytokine production and surface marker expression in acute and stable multiple sclerosis: Altered IL-12 production and augmented signalling lymphocytic activation molecule (SLAM)-expressing lymphocytes in acute multiple sclerosis. J Immunol 1998;160:15141521.
  • 28
    Isomäki P, Aversa G, Cocks BG, Luukkainen R, Saario R, Toivanen P et al. Increased expression of signalling lymphocytic activation molecule in patients with rheumatoid arthritis and its role in the regulation of cytokine production in rheumatoid synovium. J Immunol 1997;159:29862993.
  • 29
    Isomäki P, Aversa G, Chang C-CJ, Luukkainen R, Nikkari S, Toivanen P et al. Expression of soluble human signalling lymphocytic activation molecule in vivo. J Allergy Clin Immunol 1998;103:114118.
  • 30
    Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002;32:507514.
  • 31
    Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005;95: 3844.
  • 32
    Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003;14:216221.
  • 33
    Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-toTh1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol 1997;27:11311139.
  • 34
    Akdis CA, Blesken T, Akdis M, Wütrich B, Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998;102:98106.
  • 35
    Secrist H, Chelen CJ, Wen J, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 1993;178: 21232130.
  • 36
    Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995;154:41874194.